Inspired Entertainment, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Inspired Entertainment, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $199.80M | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | $31.00M | May 10, 2021 |
| FY2017 | Sep 30, 2017 | $45.05M | Dec 4, 2017 |
| FY2017 | Sep 24, 2016 | $47.72M | Dec 4, 2017 |
| FY2017 | Sep 26, 2015 | $50.78M | Dec 4, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $304.10M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $297.10M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $322.90M | Mar 26, 2025 |
| FY2024 | Dec 31, 2022 | $284.50M | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | $205.80M | Apr 15, 2024 |
| FY2022 | Dec 31, 2020 | $198.30M | Feb 27, 2024 |
| FY2021 | Dec 31, 2019 | $153.40M | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | $30.70M | May 10, 2021 |
| FY2019 | Sep 30, 2018 | $141.40M | May 10, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Sep 30, 2017 | $35.14M | Dec 4, 2017 |
| FY2017 | Jun 30, 2017 | $32.31M | Dec 4, 2017 |
| FY2017 | Mar 31, 2017 | $28.06M | Dec 4, 2017 |
| FY2017 | Dec 31, 2016 | $27.04M | Dec 4, 2017 |
| FY2017 | Sep 24, 2016 | $29.11M | Dec 4, 2017 |
| FY2017 | Jun 30, 2016 | $29.41M | Dec 4, 2017 |
| FY2017 | Mar 31, 2016 | $30.44M | Dec 4, 2017 |
| FY2017 | Dec 31, 2015 | $30.82M | Dec 4, 2017 |
| FY2017 | Sep 26, 2015 | $127.57M | Dec 4, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($17.00M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $64.80M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $6.90M | Mar 26, 2025 |
| FY2024 | Dec 31, 2022 | $21.20M | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | ($40.60M) | Apr 15, 2024 |
| FY2020 | Dec 31, 2020 | $3.10M | May 10, 2021 |
| FY2020 | Sep 30, 2020 | $500.0K | May 10, 2021 |
| FY2020 | Jun 30, 2020 | ($26.20M) | May 10, 2021 |
| FY2020 | Mar 31, 2020 | ($9.80M) | May 10, 2021 |
| FY2020 | Dec 31, 2019 | ($11.10M) | May 10, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.50M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $30.70M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $38.90M | Mar 26, 2025 |
| FY2024 | Dec 31, 2022 | $46.50M | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | ($4.50M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2020 | ($18.00M) | Feb 27, 2024 |
| FY2021 | Dec 31, 2019 | ($13.00M) | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | ($2.40M) | May 10, 2021 |
| FY2019 | Sep 30, 2018 | ($7.30M) | May 10, 2021 |
| FY2017 | Sep 30, 2017 | $210.0K | Dec 4, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.40M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $22.70M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $20.30M | Mar 26, 2025 |
| FY2024 | Dec 31, 2022 | $18.30M | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | $13.80M | Apr 15, 2024 |
| FY2022 | Dec 31, 2020 | $15.10M | Feb 27, 2024 |
| FY2021 | Dec 31, 2019 | $3.80M | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | $800.0K | May 10, 2021 |
| FY2019 | Sep 30, 2018 | $4.80M | May 10, 2021 |
| FY2018 | Sep 30, 2017 | $5.24M | Dec 10, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $104.30M | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $91.10M | Apr 15, 2024 |
| FY2023 | Dec 31, 2021 | $77.30M | Apr 15, 2024 |
| FY2022 | Dec 31, 2020 | $67.60M | Feb 27, 2024 |
| FY2021 | Dec 31, 2019 | $70.40M | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | $15.30M | May 10, 2021 |
| FY2019 | Sep 30, 2018 | $60.10M | May 10, 2021 |
| FY2017 | Sep 30, 2017 | $16.38M | Dec 4, 2017 |
| FY2017 | Jun 30, 2017 | $13.79M | Dec 4, 2017 |
| FY2017 | Mar 31, 2017 | $14.40M | Dec 4, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.00M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $31.70M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $54.70M | Mar 26, 2025 |
| FY2024 | Dec 31, 2022 | $29.60M | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | $2.40M | Apr 15, 2024 |
| FY2022 | Dec 31, 2020 | $47.80M | Feb 27, 2024 |
| FY2021 | Dec 31, 2019 | $30.70M | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | $800.0K | May 10, 2021 |
| FY2019 | Sep 30, 2018 | $34.20M | May 10, 2021 |
| FY2018 | Sep 30, 2017 | $18.25M | Dec 10, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.70M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $17.00M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $32.00M | Mar 26, 2025 |
| FY2024 | Dec 31, 2022 | $20.60M | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | $11.30M | Apr 15, 2024 |
| FY2022 | Dec 31, 2020 | $15.30M | Feb 27, 2024 |
| FY2021 | Dec 31, 2019 | $10.50M | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | $3.20M | May 10, 2021 |
| FY2019 | Sep 30, 2018 | $24.80M | May 10, 2021 |
| FY2018 | Sep 30, 2017 | $15.12M | Dec 10, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $439.90M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $438.40M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $343.00M | Mar 26, 2025 |
| FY2024 | Dec 31, 2022 | $290.00M | Mar 26, 2025 |
| FY2022 | Dec 31, 2021 | $308.70M | Feb 27, 2024 |
| FY2021 | Dec 31, 2020 | $324.10M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $327.40M | May 10, 2021 |
| FY2019 | Dec 31, 2018 | $186.70M | May 10, 2021 |
| FY2019 | Sep 30, 2018 | $207.90M | May 10, 2021 |
| FY2018 | Sep 30, 2017 | $219.02M | Dec 10, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $456.10M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $441.70M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $418.90M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | $372.80M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $417.40M | Feb 27, 2024 |
| FY2021 | Dec 31, 2020 | $425.80M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $386.70M | May 10, 2021 |
| FY2019 | Sep 30, 2018 | $232.40M | May 10, 2021 |
| FY2018 | Sep 30, 2017 | $221.35M | Dec 10, 2018 |
| FY2017 | Sep 24, 2016 | $485.94M | Dec 4, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.20M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($3.30M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | ($75.90M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | ($82.80M) | Mar 26, 2025 |
| FY2024 | Dec 31, 2021 | ($106.50M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2020 | ($128.80M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2019 | ($61.70M) | Feb 27, 2024 |
| FY2021 | Dec 31, 2018 | ($24.10M) | Mar 31, 2022 |
| FY2019 | Sep 30, 2018 | ($24.50M) | May 10, 2021 |
| FY2019 | Sep 30, 2017 | ($48.20M) | May 10, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.10M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $57.80M | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | $58.80M | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | $55.50M | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | $62.20M | Apr 15, 2024 |
| FY2022 | Dec 31, 2020 | $63.00M | Feb 27, 2024 |
| FY2021 | Dec 31, 2019 | $80.90M | Mar 31, 2022 |
| FY2023 | Oct 1, 2019 | 26.10M | Apr 15, 2024 |
| FY2020 | Dec 31, 2018 | $44.90M | May 10, 2021 |
| FY2019 | Sep 30, 2018 | $45.80M | May 10, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($458.90M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($441.50M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($506.30M) | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | ($514.60M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($524.80M) | Feb 27, 2024 |
| FY2021 | Dec 31, 2020 | ($457.40M) | Mar 31, 2022 |
| FY2020 | Sep 30, 2020 | ($460.50M) | May 10, 2021 |
| FY2020 | Jun 30, 2020 | ($461.00M) | May 10, 2021 |
| FY2020 | Mar 31, 2020 | ($434.80M) | May 10, 2021 |
| FY2020 | Dec 31, 2019 | ($425.00M) | May 10, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $47.10M | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | $29.10M | Mar 29, 2021 |
| FY2020 | Dec 31, 2018 | $16.00M | Mar 29, 2021 |
| FY2015 | Dec 31, 2015 | $256.2K | Mar 15, 2016 |
| FY2015 | Dec 31, 2014 | $1.12M | Mar 15, 2016 |
| FY2015 | May 29, 2014 | $0 | Mar 15, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $363.20M | Mar 10, 2026 |
| FY2024 | Dec 31, 2024 | $313.20M | Mar 26, 2025 |
| FY2023 | Dec 31, 2023 | $318.70M | Apr 15, 2024 |
| FY2022 | Dec 31, 2022 | $282.90M | Feb 27, 2024 |
| FY2021 | Dec 31, 2021 | $316.70M | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | $313.30M | May 10, 2021 |
| FY2020 | Dec 31, 2019 | $270.50M | Mar 29, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 26, 2025 |
| FY2024 | Dec 31, 2022 | 0 | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Apr 15, 2024 |
| FY2020 | Dec 31, 2020 | 0 | May 10, 2021 |
| FY2020 | Sep 30, 2020 | 0 | May 10, 2021 |
| FY2020 | Jun 30, 2020 | (1) | May 10, 2021 |
| FY2020 | Mar 31, 2020 | 0 | May 10, 2021 |
| FY2020 | Dec 31, 2019 | 0 | May 10, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 26, 2025 |
| FY2024 | Dec 31, 2022 | 0 | Mar 26, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Apr 15, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 27, 2024 |
| FY2019 | Dec 31, 2019 | (1) | May 10, 2021 |
| FY2019 | Dec 31, 2018 | 0 | May 10, 2021 |
| FY2019 | Sep 30, 2018 | 0 | May 10, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 26.87M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 26.58M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 26.22M | Mar 26, 2025 |
| FY2023 | Dec 31, 2022 | 25.91M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 26.43M | Feb 27, 2024 |
| FY2021 | Dec 31, 2020 | 22.43M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 22.23M | May 10, 2021 |
| FY2019 | Sep 30, 2018 | 20.86M | May 10, 2021 |
| FY2018 | Sep 30, 2017 | 20.40M | Dec 10, 2018 |
| FY2017 | Sep 24, 2016 | 11.80M | Dec 4, 2017 |